Nurix Therapeutics Stock Alpha and Beta Analysis
| NRIX Stock | USD 13.59 0.40 3.03% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Nurix Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Nurix Therapeutics over a specified time horizon. Remember, high Nurix Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Nurix Therapeutics' market risk premium analysis include:
Beta 1.35 | Alpha (0.39) | Risk 3.5 | Sharpe Ratio (0.18) | Expected Return (0.65) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Nurix |
Nurix Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Nurix Therapeutics market risk premium is the additional return an investor will receive from holding Nurix Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Nurix Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Nurix Therapeutics' performance over market.| α | -0.39 | β | 1.35 |
Nurix Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Nurix Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Nurix Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Nurix Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Nurix Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Nurix Therapeutics shares will generate the highest return on investment. By understating and applying Nurix Therapeutics stock market price indicators, traders can identify Nurix Therapeutics position entry and exit signals to maximize returns.
Nurix Therapeutics Return and Market Media
The median price of Nurix Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 19.11 with a coefficient of variation of 12.13. The daily time series for the period is distributed with a sample standard deviation of 2.22, arithmetic mean of 18.35, and mean deviation of 1.81. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 5760 shares by Christine Ring of Nurix Therapeutics at 19.4956 subject to Rule 16b-3 | 01/02/2025 |
2 | Nurix Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - Inkl | 01/14/2025 |
3 | Disposition of 5537 shares by Christine Ring of Nurix Therapeutics at 1.86 subject to Rule 16b-3 | 01/31/2025 |
4 | Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference | 02/04/2025 |
5 | Acquisition by Gwenn Hansen of 34300 shares of Nurix Therapeutics subject to Rule 16b-3 | 02/11/2025 |
6 | How Has Nurix Therapeutics Performed Amid Market Volatility | 02/13/2025 |
7 | Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/14/2025 |
8 | ARK Investment Management LLC Sells 686,072 Shares of Nurix Therapeutics, Inc. - MarketBeat | 02/26/2025 |
9 | Insider Sell Alert Houte Van Sells Shares of Nurix Therapeutics Inc | 03/04/2025 |
10 | Nurix Therapeutics, Inc. CFO Sells 84,404.25 in Stock | 03/06/2025 |
11 | Acquisition by Christine Ring of 3750 shares of Nurix Therapeutics subject to Rule 16b-3 | 03/07/2025 |
12 | Insider Trading | 03/11/2025 |
13 | Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D. ... | 03/13/2025 |
About Nurix Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Nurix or other stocks. Alpha measures the amount that position in Nurix Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 3.4 | 6.46 | 5.82 | 3.37 | Net Debt To EBITDA | 0.17 | 0.38 | 0.44 | 0.42 |
Nurix Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Nurix Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nurix Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Nurix Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Nurix Therapeutics. Please utilize our Beneish M Score to check the likelihood of Nurix Therapeutics' management manipulating its earnings.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 11th of April 2024 Next Financial Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 31st of August 2023 Last Quarter Report | View | |
| 30th of November 2022 Last Financial Announcement | View |
Build Portfolio with Nurix Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.